biopharmaceutical

Actually, and this is very surprising, most multi-billion dollar biopharmaceutical companies do not have access to scientific literature.

It could mean the government, military industrial complex, biopharmaceutical complex, the board of Alphabet, and anybody else they wish to include in it.

According to one estimate, the entire biopharmaceutical industry today boasts roughly 6,300 cubic meters in bioreactor volume.

Martha Stewart: Convicted in 2004 for insider trading related to the biopharmaceutical company ImClone Systems.

One can make arguments for/against this, but for safety reasons almost all of it is now made with biopharmaceutical (bacterial recombinant) processes.

We do this by providing a suite of biopharmaceutical services that help clients across the globe transform scientific discoveries into new treatments.

I actually found out because I wanted to build a startup that used biomedical literature and biopharmaceutical companies.

Another idea would be to completely socialize all biopharmaceutical research, but that type of system would require an extremely radical societal shift.

Not that different than what is currently done in biopharmaceutical research.

As someone who works in the biopharmaceutical industry, I couldn't disagree with you more.

I’m Kyle, a backend software engineer with 9+ years of experience building enterprise-grade, distributed, event-driven systems in the clean energy and biopharmaceutical sectors.

- Worldwide biopharmaceutical R&D was estimated to amount to USD$276B in 2021.[5] More conservative estimates include USD$102 in 2024.[6] Using the larger estimate, USD$1T buys 3.5 years of global biopharmaceutical R&D.

> with the exception of Frist a quick read shows no connection to healthcare Well, there's also Shultz, who was "a director at biopharmaceutical company Gilead Sciences," according to this article.

I am an endocrinologist working in the biopharmaceutical industry, and it surprises me that we still need to scapegoat drugs like insulin for high drug prices (“Injecting Some Insulin Reality,” Review & Outlook, April 6).